Answers are grounded in this paper and cite their sources.
We examined the characteristic changes of hepatitis B virus (HBV) in antiviral drug treatment-naive patients referred for pretreatment evaluation in Taiwan during 2008-2012. Over time, we observed substantial decreases in the prevalence of HBV e antigen (HBeAg) and increasing prevalence of the precore G1899A mutation and HBV-DNA levels in HBeAg-positive patients.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: